Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

Update Il y a 4 ans
Reference: EUCTR2014-004928-21

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the effect of ruxolitinib in delaying progression of MF from early disease to more advanced disease stages.


Inclusion criteria

  • Early Myelofibrosis patients with high molecular risk mutations